Narcolepsy without cataplexy (sudden loss of muscle tone), or NT2, can impose a significant burden on daily life. Researchers are working to identify treatment options that may help individuals with this disorder.

The KYRA Study is evaluating the safety and effectiveness of an investigational drug for NT2. Participants will be randomly assigned to receive either the investigational drug or a placebo (a substance that looks like the investigational drug but does not contain any active ingredients) for the first 8 weeks of the study treatment period. For the final 4 weeks, all participants will receive the investigational drug. Throughout the study, participants will complete various study tests and procedures.

Neither participants nor the study team will know if participants are receiving the investigational drug or a placebo during the first 8 weeks. Participants will complete up to 10 scheduled study visits, including some overnight visits. The total study duration will be up to 25 weeks.  

You can play a role in helping researchers find more ways to study and treat NT2 by participating in this clinical research study.